L Mileshkin
Overview
Explore the profile of L Mileshkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westphalen C, Federer-Gsponer J, Pauli C, Karapetyan A, Chalabi N, Duran-Pacheco G, et al.
ESMO Open
. 2023 Nov;
8(6):102035.
PMID: 37922692
Background: Patients with unfavorable carcinoma of unknown primary origin (CUP) have an extremely poor prognosis of ∼1 year or less, stressing the need for more tailored treatments, which are currently...
2.
Kramer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, et al.
Ann Oncol
. 2022 Dec;
34(3):228-246.
PMID: 36563965
No abstract available.
3.
Gordon L, Wood C, Tothill R, Webb P, Schofield P, Mileshkin L
Pharmacoecon Open
. 2022 Oct;
7(1):111-120.
PMID: 36253664
Background: Little is known about the healthcare resource usage and costs for patients with cancer of unknown primary (CUP). Objective: The aim of this study was to describe and quantify...
4.
OMalley D, Bariani G, Cassier P, Marabelle A, Hansen A, De Jesus Acosta A, et al.
Gynecol Oncol
. 2022 Jul;
166(2):245-253.
PMID: 35835611
Objective: Pembrolizumab demonstrated a clinically meaningful objective response rate in patients with previously treated, advanced MSI-H/dMMR endometrial cancer in the multicohort phase 2 KEYNOTE-158 study (ClinicalTrials.gov, NCT02628067). We present health-related...
5.
Tabernero J, Andre F, Blay J, Bustillos A, Fear S, Ganta S, et al.
ESMO Open
. 2022 Mar;
7(2):100419.
PMID: 35305400
Background: The programmed death-ligand 1 inhibitor atezolizumab had shown clinical activity against several advanced malignancies. Patients And Methods: This phase II, open-label basket study (NCT02458638) was conducted in 16 main...
6.
Khaw P, Do V, Lim K, Cunninghame J, DIXON J, Vassie J, et al.
Clin Oncol (R Coll Radiol)
. 2021 Dec;
34(3):198-204.
PMID: 34903431
Aims: Quality assurance in radiotherapy (QART) is essential to ensure the scientific integrity of a clinical trial. This paper reports the findings of the retrospective QART assessment for all centres...
7.
Edmondson R, OConnell R, Banerjee S, Mileshkin L, Sykes P, Beale P, et al.
Gynecol Oncol
. 2021 Oct;
163(3):524-530.
PMID: 34625284
Background: Aromatase inhibitors have been used empirically to treat a subset of patients with hormone receptor positive uterine leiomyosarcomas(LMS) and carcinosarcomas (UCS) mainly supported by retrospective data. We evaluated the...
8.
Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, et al.
ESMO Open
. 2021 Aug;
6(5):100224.
PMID: 34461484
Background: The COVID-19 pandemic has had a vast impact on cancer service delivery around the world. Previously reported results from our international survey of oncology clinicians, conducted through March-April 2020,...
9.
Friedlander M, Benson C, OConnell R, Reed N, Clamp A, Lord R, et al.
Gynecol Oncol
. 2021 Feb;
161(1):160-165.
PMID: 33608144
Background: Aromatase inhibitors are standard of care for low-grade endometrial stromal sarcomas (LGESS), based on very high response rates reported in retrospective studies. We evaluated the activity of anastrozole in...
10.
Schofield P, Gough K, Pascoe M, Bergin R, White K, Mileshkin L, et al.
Gynecol Oncol
. 2020 Sep;
159(3):785-793.
PMID: 32962898
Objective: Radiotherapy for gynaecological cancer is associated with multiple adverse effects. This randomised controlled trial evaluated the impact of a combined nurse- and peer-led psycho-educational intervention on psychological distress, preparation...